In a recent CBS News New York interview, Dotmatics VP of Science and Technology, Phil Mounteney, shares how artificial intelligence is reshaping the drug discovery process—helping researchers accelerate timelines, reduce costs, and deliver safer, more effective therapies to market.
By using AI to analyze scientific data generated in early-phase research, Dotmatics enables teams to cut years off traditional development cycles for vaccines and personalized medicine. These AI models are built and stored internally—ensuring data privacy while driving innovation at scale.
Watch the full interview to learn how Dotmatics is helping the healthcare industry move faster and smarter toward breakthrough cures.
Learn More About Dotmatics
Schedule a meeting with our team to learn more about Luma's AI capabilities.